Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Pegtibatinase · OT-058, TVT-058

Recombinant protein · developed by Travere Therapeutics

Phase 3 Most advanced trial
TVTX Developer
1 Registered trials

What is Pegtibatinase?

Pegtibatinase is a pegylated recombinant enzyme derived from cystathionine beta-synthase (CBS), a human enzyme that converts homocysteine. It is being studied in homocystinuria, a metabolic disorder marked by elevated homocysteine levels.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
OT-058, TVT-058, OT-58
Drug type
Recombinant protein
Therapy area
Neurology
Developer
Travere Therapeutics, Inc. (TVTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
3G3529LUQ7

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06247085 Phase 3 Homocystinuria Recruiting TVTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Homocystinuria

More from Travere Therapeutics

Follow TVTX, the company behind Pegtibatinase

See TVTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TVTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.